Drug intelligence / Profile preview

RBT-402

Development stage: Preclinical
Lead developer: Artgen Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

RBT-402 is a recombinant protein subunit vaccine being developed by Artgen Biotech for the prevention of Human Papillomavirus (HPV) infection. The vaccine utilizes the Betusphere platform, which incorporates surface recombinant proteins onto spherical adjuvant particles. These particles are virus-like particles (VLPs) created using a patented technology based on betulin, an organic substance derived from birch bark. This adjuvant system is designed to enhance the immune response to the recombinant HPV antigens. RBT-402 is currently in preclinical development.

Beyond the preview

Go deeper on RBT-402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBT-402.

Explore the full profile